Oleh Taratula

Dr. Oleh Taratula

Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Portland, Oregon 97201, United States
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2023 in Science Advances
Verified
Journal Article
Closed access
MHMarco Herrera-Barrera
Marco Herrera-Barrera
RRRenee Ryals
Renee Ryals
MGMilan Gautam
Milan Gautam
AJAntony Jozic
Antony Jozic
MLMadeleine Landry
Madeleine Landry
GSGaurav Sahay
Gaurav Sahay
Lipid nanoparticle (LNP)–based mRNA delivery holds promise for the treatment of inherited retinal degenerations. Currently, LNP-mediated mRNA delivery is restricted to the retinal pigment epithelium (RPE) and Müller glia. LNPs must overcome ocular barriers to transfect neuronal cells critical for visual phototransduction, the photoreceptors (PRs). We used a combinatorial M13 bacteriophage–based heptameric peptide phage display library for the mining of peptide ligands that target PRs. We identified the most promising peptide candidates resulting from in vivo biopanning. Dye-conjugated peptides showed rapid localization to the PRs. LNPs decorated with the top-performing peptide ligands delivered mRNA to the PRs, RPE, and Müller glia in mice. This distribution translated to the nonhuman primate eye, wherein robust protein expression was observed in the PRs, Müller glia, and RPE. Overall, we have developed peptide-conjugated LNPs that can enable mRNA delivery to the neural retina, expanding the utility of LNP-mRNA therapies for inherited blindness.

10 October 2011 in Journal of Drug Targeting
Verified
Journal Article
Closed access
PDF file
OTOleh Taratula
Oleh Taratula
OGOlga B. Garbuzenko
Olga B. Garbuzenko
ACAlex M. Chen
Alex M. Chen
TMTamara Minko
Tamara Minko
A tumor targeted mesoporous silica nanoparticles (MSN)-based drug delivery system (DDS) was developed for inhalation treatment of lung cancer. The system was capable of effectively delivering inside cancer cells anticancer drugs (doxorubicin and cisplatin) combined with two types of siRNA targeted to MRP1 and BCL2 mRNA for suppression of pump and nonpump cellular resistance in non-small cell lung carcinoma, respectively. Targeting of MSN to cancer cells was achieved by the conjugation of LHRH peptide on the surface of MSN via poly(ethylene glycol) spacer. The delivered anticancer drugs and siRNA preserved their specific activity leading to the cell death induction and inhibition of targeted mRNA. Suppression of cellular resistance by siRNA effectively delivered inside cancer cells and substantially enhanced the cytotoxicity of anticancer drugs. Local delivery of MSN by inhalation led to the preferential accumulation of nanoparticles in the mouse lungs, prevented the escape of MSN into the systemic circulation, and limited their accumulation in other organs. The experimental data confirm that the developed DDS satisfies the major prerequisites for effective treatment of non-small cell lung carcinoma. Therefore, the proposed cancer-targeted MSN-based system for complex delivery of drugs and siRNA has high potential in the effective treatment of lung cancer.

13 May 2019 in ACS Nano
Verified
Journal Article
Closed access
HAHassan A Albarqi
Hassan A Albarqi
LWLeon H Wong
Leon H Wong
CSCanan Schumann
Canan Schumann
FSFahad Y. Sabei
Fahad Y. Sabei
TKTetiana Korzun
Tetiana Korzun
OTOleh Taratula
Oleh Taratula

10 September 2013 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
OTOleh Taratula
Oleh Taratula
CSCanan Schumann
Canan Schumann
MNMichael A. Naleway
Michael A. Naleway
APAddison J. Pang
Addison J. Pang
KCKaitlyn J. Chon
Kaitlyn J. Chon

12 November 2014 in Nanoscale
Verified
Journal Article
Closed access
PDF file
OTOleh Taratula
Oleh Taratula
CSCanan Schumann
Canan Schumann
TDTony Duong
Tony Duong
KTKarmin L. Taylor
Karmin L. Taylor
Multifunctional theranostic platforms capable of concurrent near-infrared (NIR) fluorescence imaging and phototherapies are strongly desired for cancer diagnosis and treatment. However, the integration of separate imaging and therapeutic components into nanocarriers results in complex theranostic systems with limited translational potential. A single agent-based theranostic nanoplatform, therefore, was developed for concurrent NIR fluorescence imaging and combinatorial phototherapy with dual photodynamic (PDT) and photothermal (PTT) therapeutic mechanisms. The transformation of a substituted silicon naphthalocyanine (SiNc) into a biocompatible nanoplatform (SiNc-NP) was achieved by SiNc encapsulation into the hydrophobic interior of a generation 5 polypropylenimine dendrimer following surface modification with polyethylene glycol. Encapsulation provides aqueous solubility to SiNc and preserves its NIR fluorescence, PDT and PTT properties. Moreover, an impressive photostability in the dendrimer-encapsulated SiNc has been detected. Under NIR irradiation (785 nm, 1.3 W cm−2), SiNc-NP manifested robust heat generation capability (ΔT = 40 °C) and efficiently produced reactive oxygen species essential for PTT and PDT, respectively, without releasing SiNc from the nanopaltform. By varying the laser power density from 0.3 W cm−2 to 1.3 W cm−2 the therapeutic mechanism of SiNc-NP could be switched from PDT to combinatorial PDT–PTT treatment. In vitro and in vivo studies confirmed that phototherapy mediated by SiNc can efficiently destroy chemotherapy resistant ovarian cancer cells. Remarkably, solid tumors treated with a single dose of SiNc-NP combined with NIR irradiation were completely eradicated without cancer recurrence. Finally, the efficiency of SiNc-NP as an NIR imaging agent was confirmed by recording the strong fluorescence signal in the tumor, which was not photobleached during the phototherapeutic procedure.

1 January 2018 in Theranostics
Verified
Journal Article
Open access
XLXiaoning Li
Xiaoning Li
CSCanan Schumann
Canan Schumann
HAHassan A Albarqi
Hassan A Albarqi
CLChristopher J Lee
Christopher J Lee
Adam AlaniAdam Alani
Adam Alani
OTOleh Taratula
Oleh Taratula
Fluorescence image-guided surgery combined with intraoperative therapeutic modalities has great potential for intraoperative detection of oncologic targets and eradication of unresectable cancer residues. Therefore, we have developed an activatable theranostic nanoplatform that can be used concurrently for two purposes: (1) tumor delineation with real-time near infrared (NIR) fluorescence signal during surgery, and (2) intraoperative targeted treatment to further eliminate unresected disease sites by non-toxic phototherapy.